Monthly Alternating NALIRIFOX and GnP in the First-Line Setting

NCT IDNCT07163273ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

Phase 2

Target enrollment

Study length

about 2 years

Ages

18+

Locations

7 sites in NY

What this study is about

Researchers are testing whether a treatment of monthly alternating NALIRIFOX and Gemcitabine plus nab-Paclitaxel (GnP) improves outcomes for people with pancreatic cancer compared to standard care. The trial will last about 730 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

1.Take Gemcitabine plus nab-Paclitaxel (GnP)
2.Take NALIRIFOX

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Injection / IVInjection / IV

How treatment is administered

Treatment Assignment

All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)

Drug routes

injection (Injection), infusion

Endpoints

Primary: Determine 6-month Progression Free Survival (PFS)

Secondary: Disease Control Rate, Overall Response Rate, Overall Survival, Time to Treatment Failure

Screen for this study View on ClinicalTrials.gov